Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study
American Journal of Cancer Research · 2026 · 16 (6) · 2503-2517
DOI: 10.62347/dccq4239 ↗At a glance
Kohortenstudie in American Journal of Cancer Research, 2026. Written by Qinghai Fu and 3 co-authors. Institution: Department of Gastroenterology, Sinopharm Dongfeng General Hospital Shiyan 442008, Hubei, China. The full text is freely available in PubMed Central.
Abstract (original language)
Intet abstract tilgængeligt.
Subjects
Author keywords
Authors and institutions
- Department of Gastroenterology, Sinopharm Dongfeng General Hospital Shiyan 442008, Hubei, China.
- Department of Gastrointestinal Surgery, Sinopharm Dongfeng General Hospital Shiyan 442008, Hubei, China.
Cite
APA
Fu, Q., Wang, X., Zheng, S., & Wang, W. (2026). Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study. American Journal of Cancer Research, 16(6), 2503-2517. https://doi.org/10.62347/dccq4239
Vancouver
Fu Q, Wang X, Zheng S, Wang W. Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study. American Journal of Cancer Research. 2026;16(6):2503-2517. doi:10.62347/dccq4239
BibTeX
@article{Fu2026,
author = {Fu, Qinghai and Wang, Xiaolong and Zheng, Shiqin and Wang, Wei},
title = {Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study},
journal = {American Journal of Cancer Research},
year = {2026},
volume = {16},
number = {6},
pages = {2503--2517},
doi = {10.62347/dccq4239}
}
EUVIMED